Welcome to our dedicated page for I-Mab news (Ticker: IMAB), a resource for investors and traders seeking the latest updates and insights on I-Mab stock.
I-Mab (NASDAQ: IMAB), now known as NovaBridge Biosciences, generates a steady flow of news as a U.S.-based, global biotech company focused on precision immuno-oncology. Investors following IMAB-related headlines can track how the company advances its lead Claudin 18.2 x 4-1BB bispecific antibody, givastomig, and other pipeline assets through clinical milestones, strategic transactions, and capital markets activity.
News coverage commonly highlights clinical data from Phase 1 and Phase 1b studies of givastomig in Claudin 18.2-positive gastric and gastroesophageal cancers, including monotherapy results and combination regimens with immunochemotherapy in the first-line metastatic setting. Company announcements describe objective response rates, safety findings, and study design details from presentations at major oncology conferences such as ESMO GI and the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics meeting.
Beyond clinical readouts, IMAB news items also cover the company’s broader transformation into a global biotech platform under the NovaBridge Biosciences name. Releases discuss the adoption of a hub-and-spoke business model, the formation of subsidiaries like Visara, Inc. for VIS-101 in ophthalmology, and strategic agreements with partners including ABL Bio, AffaMed Therapeutics, AskGene Pharma, and Everest Medicines. Capital markets updates, such as underwritten offerings of American Depositary Shares and intentions to pursue a dual listing on the Hong Kong Stock Exchange, are also key themes.
On this news page, readers can review company press releases, SEC-referenced announcements, and other IMAB-related updates in one place. For investors and researchers, regularly checking this feed offers insight into clinical progress, partnership activity, governance changes, and financing events that shape the outlook for I-Mab’s, and NovaBridge Biosciences’, oncology and ophthalmology programs.
I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company focused on cancer immunotherapies, has appointed PricewaterhouseCoopers LLP (PwC US) as its independent registered public accounting firm for fiscal year 2024. This decision, approved by the Audit Committee, is part of I-Mab's strategic transition to become a fully U.S.-based biotech company. The change aims to ensure compliance with the Holding Foreign Companies Accountable Act and aligns with the company's long-term growth objectives.
Interim CEO Sean Fu emphasized that this appointment marks a significant milestone in I-Mab's U.S. transition strategy. CFO Joseph Skelton expressed enthusiasm about working with PwC US, viewing it as beneficial for shareholders. The company assures that this transition was not due to any disagreements or issues with the previous auditor.
I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company, has announced significant leadership changes. Mr. Wei Fu has been appointed as the new Chairman of the Board, replacing Dr. Pamela M. Klein. Mr. Raj Kannan is stepping down as CEO and board member, with Dr. Sean Xi-Yong Fu taking over as Interim CEO and joining the board. Dr. Fu brings extensive experience from various biotech roles, including his position as an Operating Partner at ABio-X and former CEO of RVAC Medicines.
The company also announced changes to its Board of Directors and committees, including the resignations of Dr. Ruyi He and Professor Rong Shao. These transitions aim to strengthen I-Mab's leadership as it continues its transformation into a U.S.-based biotech company, focusing on advancing its R&D pipeline and creating value for shareholders.
I-Mab (NASDAQ: IMAB) has announced the appointment of Dr. Phillip Dennis as Chief Medical Officer, effective June 17, 2024. Dr. Dennis will lead I-Mab's global clinical development and join the Executive Leadership Team. With two decades of oncology drug development experience, including key roles at Sanofi and AstraZeneca, Dr. Dennis brings significant expertise. His appointment aims to advance I-Mab's clinical pipeline, particularly for treatments like uliledlimab, givastomig, and ragistomig. Before his industry roles, Dr. Dennis was a professor at Johns Hopkins University and a senior investigator at the US National Cancer Institute.
I-Mab (NASDAQ: IMAB), a global biotech company, has announced a clinical trial collaboration with Bristol Myers Squibb (NYSE: BMY). The focus is on evaluating the combination of givastomig, a Claudin 18.2 x 4-1BB bispecific antibody, with nivolumab and chemotherapy for treating advanced gastric and esophageal cancers. The collaboration leverages promising safety and efficacy data from givastomig's monotherapy study, presented at the European Society of Medical Oncology Congress 2023. The multi-national Phase 1 study will be conducted by I-Mab, with Bristol Myers Squibb supplying nivolumab. The aim is to explore the potential of this combination as a first-line treatment for Claudin 18.2-positive cancers.
I-Mab (NASDAQ: IMAB) announced promising Phase 1 clinical data for its bispecific antibody ragistomig (PD-L1x4-1BB) at the 2024 ASCO Annual Meeting. The data revealed a manageable safety profile and encouraging efficacy in heavily pre-treated patients, including 1 complete response (CR) and 6 partial responses (PR). Ragistomig demonstrated an overall response rate (ORR) of 25% at the optimal dose of 5 mg/kg, with a clinical benefit rate (CBR) of 75%. The study included patients with advanced or relapsed/refractory solid tumors, with 71.4% of responders having received prior anti-PD-(L1) therapy. I-Mab highlighted the potential of ragistomig as both monotherapy and in combination with other treatments. The data will be presented by Dr. Gerald Falchook on June 1, 2024, at the ASCO meeting in Chicago.
I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company specializing in immunotherapies for cancer treatment, announced its participation in the Jefferies Global Healthcare Conference on June 5, 2024.
Key presenters include CEO Raj Kannan and Interim CMO Louie Naumovski, with the presentation scheduled for 9:30 a.m. EST. The event will feature one-on-one and small group meetings with key management members, including CFO Joe Skelton and Senior Director of Investor Relations Tyler Ehler.
The presentation will be available via webcast on I-Mab's Investor Relations website.
I-Mab, a global biotech company, filed its 2023 annual report on Form 20-F with the SEC. The report focuses on the development of immunotherapies for cancer treatment. It can be accessed on the company's investor relations website and the SEC's website. Shareholders and ADS holders can request hard copies free of charge.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of I-Mab (IMAB)?
What is the market cap of I-Mab (IMAB)?
